Elevance Health (NYSE:ELV) Updates FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 19.850- for the period, compared to the consensus earnings per share estimate of 25.810. The company issued revenue guidance of -.

Elevance Health Stock Up 2.7%

Shares of ELV opened at $327.87 on Wednesday. The stock has a fifty day simple moving average of $308.88 and a two-hundred day simple moving average of $331.60. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $72.02 billion, a PE ratio of 13.05, a price-to-earnings-growth ratio of 1.77 and a beta of 0.49. Elevance Health has a 52-week low of $273.71 and a 52-week high of $432.93.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts forecast that Elevance Health will post 25.82 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.39%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Barclays cut their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. UBS Group set a $400.00 price objective on Elevance Health in a research report on Thursday, January 29th. Sanford C. Bernstein cut their price objective on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Finally, Truist Financial cut their price objective on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Twelve investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $383.38.

Hedge Funds Weigh In On Elevance Health

Institutional investors have recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new position in Elevance Health in the 4th quarter valued at about $31,000. J.Safra Asset Management Corp acquired a new position in Elevance Health in the 4th quarter valued at about $32,000. Jessup Wealth Management Inc acquired a new position in Elevance Health in the 4th quarter valued at about $45,000. Garton & Associates Financial Advisors LLC acquired a new position in Elevance Health in the 4th quarter valued at about $50,000. Finally, Rossby Financial LCC boosted its stake in shares of Elevance Health by 85.7% in the 4th quarter. Rossby Financial LCC now owns 156 shares of the company’s stock valued at $55,000 after buying an additional 72 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.